Holocene Advisors LP Has $2.84 Million Stake in Denali Therapeutics Inc. (NASDAQ:DNLI)

Holocene Advisors LP raised its position in Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 65.0% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 97,447 shares of the company's stock after purchasing an additional 38,405 shares during the quarter. Holocene Advisors LP owned about 0.07% of Denali Therapeutics worth $2,839,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently made changes to their positions in DNLI. GAMMA Investing LLC increased its position in Denali Therapeutics by 879.5% in the 2nd quarter. GAMMA Investing LLC now owns 2,057 shares of the company's stock valued at $48,000 after acquiring an additional 1,847 shares during the period. SG Americas Securities LLC raised its stake in shares of Denali Therapeutics by 93.4% during the second quarter. SG Americas Securities LLC now owns 13,808 shares of the company's stock valued at $321,000 after purchasing an additional 6,667 shares in the last quarter. Hamilton Lane Advisors LLC bought a new stake in shares of Denali Therapeutics during the second quarter valued at about $596,000. MONECO Advisors LLC bought a new position in Denali Therapeutics in the 2nd quarter valued at about $202,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its position in Denali Therapeutics by 5.5% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 26,403 shares of the company's stock valued at $613,000 after buying an additional 1,372 shares in the last quarter. Institutional investors own 92.92% of the company's stock.

Denali Therapeutics Stock Up 6.7 %

Shares of Denali Therapeutics stock traded up $1.57 during midday trading on Friday, hitting $24.89. The company's stock had a trading volume of 513,278 shares, compared to its average volume of 1,059,177. Denali Therapeutics Inc. has a 1-year low of $14.56 and a 1-year high of $33.33. The firm has a market capitalization of $3.58 billion, a P/E ratio of -8.99 and a beta of 1.35. The stock has a 50-day simple moving average of $26.85 and a 200-day simple moving average of $24.58.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.63) EPS for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.03). During the same period in the previous year, the business posted ($0.72) earnings per share. As a group, sell-side analysts predict that Denali Therapeutics Inc. will post -2.69 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the stock. JPMorgan Chase & Co. reduced their price target on shares of Denali Therapeutics from $29.00 to $28.00 and set an "overweight" rating for the company in a research note on Friday, October 11th. HC Wainwright reiterated a "buy" rating and set a $90.00 price target on shares of Denali Therapeutics in a research report on Thursday, November 7th. Raymond James reaffirmed a "market perform" rating on shares of Denali Therapeutics in a research note on Thursday, October 10th. Jefferies Financial Group boosted their price target on shares of Denali Therapeutics from $40.00 to $45.00 and gave the stock a "buy" rating in a research report on Friday, November 1st. Finally, Bank of America lifted their price objective on shares of Denali Therapeutics from $25.00 to $29.00 and gave the stock a "buy" rating in a research note on Wednesday, September 4th. Three investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $38.90.

Insider Activity at Denali Therapeutics

In related news, CEO Ryan J. Watts sold 40,000 shares of Denali Therapeutics stock in a transaction on Friday, October 18th. The stock was sold at an average price of $27.69, for a total transaction of $1,107,600.00. Following the completion of the sale, the chief executive officer now owns 235,807 shares of the company's stock, valued at approximately $6,529,495.83. This trade represents a 14.50 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Vicki L. Sato sold 1,020 shares of the company's stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $30.00, for a total value of $30,600.00. Following the completion of the transaction, the director now directly owns 111,056 shares in the company, valued at approximately $3,331,680. The trade was a 0.91 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 86,578 shares of company stock valued at $2,474,440. Corporate insiders own 7.90% of the company's stock.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.